In vivo degradation behavior of PDC multiblock copolymers containing poly(para-dioxanone) hard segments and crystallizable poly(epsilon-caprolactone) switching segments

Abstract

The degradation behavior of biodegradable multiblock copolymers (PDC) containing poly(p-dioxanone) hard segments (PPDO) and crystallizable poly(ε-caprolactone) switching segments (PCL) synthesized via co-condensation of two oligomeric macrodiols with an aliphatic diisocyanate as junction unit was explored in in vivo and in vitro experiments. The in vitro experiments for enzymatic degradation resulted that the poly(ε-caprolactone) segments are degraded faster, than the poly(p-dioxanone) segments. During degradation the outer layer of the test specimen becomes porous. Finally non-soluble degradation products in form of particles were found at the surface. This observation is in good agreement with the in vivo studies, where the non-soluble degradation products in the periimplantary tissues showed a diameter of 1 -3 micron.

In vivo evaluation of the angiogenic effects of the multiblock copolymer PDC using the hen's egg chorioallantoic membrane test

“…In this aspect, we believe PDC can be a good candidate material for future biomedical applications due to its unique tissue integration capability [8], degradation characteristic [7] and angiogenic potential. The result of this study warrants further studies on PDC as a biomaterial.…”

Shape-memory polymers as a technology platform for biomedical applications

“…Wear particle accumulation at the biomaterial-tissue-interface was described as 'particle disease', and caused concerns regarding the introduction of degradable polymers Review Shape-memory polymers as a technology platform for biomedical applications in medical therapies [94][95][96]. In in vivo and in vitro experiments, the degradation behavior of the biodegradable multiblock copolymer SMP PDC, containing PPDO hard segments and crystallizable PCL switching segments, was shown [20], synthesized via co-condensation of two oligomeric macrodiols with an aliphatic diisocyanate as a junction unit [97,98]. The study demonstrated that the in vivo degradation process of PDC is characterized by a release of microparticles, which were supposed to primarily consist of PPDO, and which didn't negatively affect a strong integration of the SMP in the subcutis of rats [97] and mice [99].…”

“…In in vivo and in vitro experiments, the degradation behavior of the biodegradable multiblock copolymer SMP PDC, containing PPDO hard segments and crystallizable PCL switching segments, was shown [20], synthesized via co-condensation of two oligomeric macrodiols with an aliphatic diisocyanate as a junction unit [97,98]. The study demonstrated that the in vivo degradation process of PDC is characterized by a release of microparticles, which were supposed to primarily consist of PPDO, and which didn't negatively affect a strong integration of the SMP in the subcutis of rats [97] and mice [99]. This might be explained by the angiogenic effect of the PDC, which was shown in the hen's egg chorioallantoic membrane test (HET-CAM-test) [71], and also after subcutaneous implantation in rats [97] (Figure 3) and mice [99].…”

Preparation of Three‐Dimensional Scaffolds from Degradable Poly(ether)esterurethane by Thermally‐Induced Phase Separation

“…[16] The thermoplastic multiblock copolymer PDC was selected as multifunctional biomaterial combining degradability and excellent elastic properties enabling a shape-memory capability. [17][18][19] For PDC a linear mass loss was reported in hydrolytic and enzymatic degradation experiments, whereby the degradation behavior could be controlled by the composition e.g. the ratio of the PCL and PPDO precursors.…”

“…[6,7,17,20] Furthermore, the in vivo degradation of PDC is characterized by a fragmentation and a pro-angiogenic effect was observed. [18,21] Experimental Part and DH…”